IONS · Ionis Pharmaceuticals Inc
Market Cap
$9.65B
Shares
166.18M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$943.71M
+33.8%
FY2025
Net Income
-$381.39M
+16%
FY2025
Gross Margin
98.31%
-0.1pp
FY2025
Operating Margin
-40.45%
+26.9pp
FY2025
Diluted EPS
-$2.38
+21.7%
FY2025
Operating Cash Flow
-$268.58M
+46.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $874.09M | $943.71M | $705.14M | $787.65M | $587.37M | $810.46MG | $729.26M | $1.12B | $599.67M | $507.67M | $346.62M | $283.7M | $214.16M | $147.29M | $102.05M | $99.09M | $108.47M | $121.6M | $107.19M | |
| $16.02M | $15.91M | $11.22M | $9.13M | $14.12M | $10.84M | $11.95M | $4.38M | $1.82M | $0 | $0 | — | — | — | — | — | — | — | — | |
| $858.07M | $927.8M | $693.92M | $778.51M | $573.25M | $799.61M | $717.32M | $1.12B | $597.85M | $507.67M | $346.62M | — | — | — | — | — | — | — | — | |
| — | 98.31% | 98.41% | 98.84% | 97.6% | 98.66% | 98.36% | 99.61% | 99.7% | 100% | 100% | — | — | — | — | — | — | — | — | |
| — | $915.62M | $901.53M | $899.63M | — | $638.2M | $531M | $461.5M | $411.9M | $372.5M | $340.4M | $319.5M | $238.9M | $173.7M | $154.6M | $153.1M | $145.16M | $134.62M | $106.44M | |
| — | — | — | — | — | — | — | — | — | — | $48.62M | $37.17M | $20.14M | $14.92M | $12.52M | $12.79M | $11.67M | $14.52M | $13.81M | |
| $527.75M | $393.87M | $267.47M | $232.62M | $150.3M | $186.35M | $354.32M | $286.64M | $244.62M | $108.49M | $48.62M | $37.17M | — | — | — | — | — | — | — | |
| $2.62M | $2.44M | $2.34M | $2.56M | $2.42M | $2.35M | $2.06M | $1.91M | $1.82M | $1.64M | $1.55M | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $661.05M | $483.13M | $392.94M | $359.47M | $261.89M | $198.95M | $170.97M | $170.19M | $156.83M | $149.14M | $120.25M | |
| $1.47B | $1.33B | $1.18B | $1.14B | $997.56M | $840.64M | $901.35M | $756.72M | $661.05M | $483.13M | — | — | — | — | — | — | — | — | — | |
| -$594.36M | -$381.68M | -$475.08M | -$353.73M | -$410.19M | -$30.19M | -$172.08M | $365.88M | -$61.37M | $31.05M | -$20.16M | -$75.76M | -$47.73M | -$51.67M | -$68.92M | -$71.1M | -$48.36M | -$27.54M | -$13.06M | |
| — | -40.45% | -67.37% | -44.91% | -69.84% | -3.72% | -23.6% | 32.59% | -10.23% | 6.12% | -5.82% | -26.7% | -22.29% | -35.08% | -67.54% | -71.76% | -44.58% | -22.65% | -12.18% | |
| $18.82M | $17.26M | $16.99M | $12.66M | $8.12M | $9.35M | $9.51M | $12.44M | $44.79M | $44.75M | $38.8M | $36.73M | $22.21M | $19.36M | $21.15M | $16.73M | $13.23M | $12.67M | $11.81M | |
| -$15.39M | -$15.36M | $1.33M | $14.1M | -$7.27M | -$9.76M | -$62K | -$686K | -$182K | -$3.55M | $0 | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | $0 | $0 | -$1.41M | -$3.55M | -$6.88M | — | — | |
| $43.1M | $10.22M | -$2.89M | -$1.91M | -$7.33M | $10.1M | $16.54M | $192K | -$210K | — | — | — | $1.26M | $2.38M | $1.47M | $4.18M | -$713K | $2.08M | -$965K | |
| -$562M | -$379.6M | -$460.07M | -$333.97M | -$257.99M | -$29.15M | -$134.55M | $338.77M | -$76.16M | -$16.76M | -$83.62M | -$87.91M | -$54.39M | -$66.56M | -$74.59M | -$84.79M | -$61.16M | -$31.77M | — | |
| $3.17M | $1.79M | -$6.17M | $32.32M | $11.74M | -$551K | $345.19M | $51.51M | -$291.14M | -$5.98M | $2.93M | $372K | -$15.41M | -$5.91M | -$9.11M | $11K | $92K | $3.19M | — | |
| -$565.17M | -$381.39M | -$453.9M | -$366.29M | -$269.72M | -$28.6M | -$444.26M | $278.14M | $273.74M | $346K | -$60.4M | -$88.28M | -$38.98M | -$60.64M | -$65.48M | -$84.8M | -$61.25M | $155.07M | -$18.17M | |
| — | -40.41% | -64.37% | -46.5% | -45.92% | -3.53% | -60.92% | 24.78% | 45.65% | 0.07% | -17.43% | -31.12% | -18.2% | -41.17% | -64.16% | -85.58% | -56.47% | 127.52% | -16.95% | |
| — | — | — | — | $0 | $0 | -$35.48M | $9.12M | -$58.76M | -$11.13M | $0 | $0 | — | — | — | — | — | -$4.39M | -$4.73M | |
| — | — | — | — | — | — | -$444.46M | $280.56M | $276.87M | $18.79M | — | — | -$38.98M | -$60.64M | -$65.48M | -$84.8M | -$61.25M | $155.07M | — | |
| -$571.08M | -$375.86M | -$452.06M | -$341.45M | -$294.53M | -$40.19M | -$440.04M | $284.87M | $273.51M | -$960K | -$77.19M | -$141.59M | -$20.32M | -$52.04M | -$52.23M | -$86.52M | -$62.46M | — | — | |
| USD/shares | -$3.46 | -$2.38 | -$3.04 | -$2.56 | -$1.90 | -$0.20 | -$3.18 | $2.00 | $2.09 | $0.15 | -$0.50 | -$0.74 | — | — | — | -$0.85 | -$0.62 | $1.58 | -$0.19 |
| USD/shares | -$3.46 | -$2.38 | -$3.04 | -$2.56 | -$1.90 | -$0.20 | -$3.18 | $1.90 | $2.07 | $0.15 | -$0.50 | -$0.74 | — | — | — | -$0.85 | -$0.62 | $1.58 | -$0.19 |
| shares | — | 160.01M | 149.51M | 143.19M | 141.85M | 141.02M | 139.61M | 140M | 132.32M | 124.02M | 120.93M | 119.72M | 117.69M | 110.5M | 100.58M | 99.66M | 99.14M | 98.11M | 94.57M |
| shares | — | 160.01M | 149.51M | 143.19M | 141.85M | 141.02M | 139.61M | 153.16M | 134.06M | 126.1M | 120.93M | 119.72M | 117.69M | 110.5M | 100.58M | 99.66M | 99.14M | 98.11M | 94.57M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2017–FY2022: $124.95M in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Coverage backlog: 82 eligible filings and 0 covenant artifacts have no current-version terminal extraction result. This includes untouched sources and sources on the retry ladder.
No terminal debt extraction result is available yet; this is not evidence that the company has no debt.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
10.05×
Peer median 9.82×
EV/EBIT
—
Peer median 29.69×
P/E (TTM)
—
Peer median 20.80×
Peer medians compare against the 148 similar-size Biotechnology companies (of 515 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Ionis Operations | $943,711,000 | $705,138,000 | $787,647,000 | $587,367,000 | — | — | — | — |
| Akcea Therapeutics | — | — | — | — | $152,320,000 | $488,543,000 | $64,867,000 | $43,401,000 |
| Ionis Core | — | — | — | — | $622,941,000 | $858,646,000 | $641,944,000 | $525,185,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Research and Development Revenue | $507,863,000 | $412,062,000 | $479,056,000 | $284,009,000 | $468,061,000 | $364,565,000 | — | — |
| Collaborative Agreement Revenue | $465,785,000 | $332,647,000 | $352,657,000 | $207,222,000 | $468,061,000 | $364,565,000 | — | — |
| Commercial | $435,848,000 | $293,076,000 | $308,591,000 | $303,358,000 | $342,395,000 | $364,699,000 | $352,450,000 | $254,922,000 |
| Royalty | $285,529,000 | $257,307,000 | $272,803,000 | — | — | — | — | — |
| Spinraza Royalties | $212,280,000 | $216,090,000 | $240,379,000 | $242,314,000 | $267,776,000 | $286,583,000 | $292,992,000 | $237,930,000 |
| Product | $115,315,000 | $0 | $0 | $30,051,000 | $55,500,000 | $69,999,000 | $42,253,000 | $2,237,000 |
| Tryngolza Sales | $107,526,000 | $0 | $0 | — | — | — | — | — |
| Wainus Royalties | $49,090,000 | $20,207,000 | $0 | $0 | — | — | — | — |
| Wainua Joint Development Revenue | $42,078,000 | $79,415,000 | $126,399,000 | $76,787,000 | $0 | — | — | — |
| Other Commercial | $35,004,000 | $35,769,000 | $35,788,000 | $61,044,000 | $74,619,000 | — | — | — |
| Other Royalties | $24,159,000 | $21,010,000 | $32,424,000 | — | — | — | — | — |
| Dawnzera Sales | $7,789,000 | $0 | $0 | — | — | — | — | — |
| Eplontersen Joint Development Revenue | — | — | — | $76,787,000 | $0 | $0 | — | — |
| Licensing and Other Royalties | — | — | $33,299,000 | $30,993,000 | $19,119,000 | $8,117,000 | $17,205,000 | $14,755,000 |
| Other | — | $22,590,000 | $33,299,000 | $30,993,000 | — | — | — | — |
| Research And Development Revenue Under Collaborative Agreements | — | — | — | — | $468,061,000 | $364,565,000 | $770,149,000 | $344,752,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|
| Ionis Core | $59,294,000 | $335,439,000 | $261,732,000 | $151,397,000 |
| Akcea Therapeutics | -$237,255,000 | $38,074,000 | -$230,816,000 | -$120,470,000 |
Operating Margin by Segment (%)
| Component | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|
| Akcea Therapeutics | -155.8% | 7.8% | -355.8% | -277.6% |
| Ionis Core | 9.5% | 39.1% | 40.8% | 28.8% |
Key facts
CIK
874015
CUSIP
462222100
13F (30d)
369 filings
367 filers
Visit website
Investor relations